Pfizer Tries Again for Sanctions Against Neurontin Witness
Pfizer (PFE) is playing hardball in its attempt to get sanctions applied to an expert in the Neurontin litigation who contacted another witness wthout the drug company’s permission. The company is asking a judge to overturn the ruling of a federal magistrate that sanctions should not be applied to Dr. David Egilman, an expert witness for plaintiffs in the case.
Download Pfizer’s motion here.Pfizer contends that Egilman sent an unfairly truncated copy of a controversial email to another witness in the case, the doctor who treated Hartley Shearer, a Massachusetts man whose family claims he killed himself after taking the drug, and is now suing Pfizer.
BNET revealed in October that the email was from former Pfizer vp/neuroscience Atul Pande, telling a colleague that there is “negligible evidence” for the use of Neurontin in bipolar disorder and that the drug is “not a good anti-manic treatment.”
In its motion objecting to federal magistrate Leo Sorokin’s ruling, Pfizer describes an interview it did with Shearer’s doctor, Lisa K. Catapano-Friedman, about Egilman’s communications with her:
A. My thoughts were that somebody was trying to influence my testimony.
Q. And how did that make you feel?
A. Insulted.Dr. Catapano-Friedman had a similar reaction upon learning that Dr. Egilman had materially altered one of the documents he had sent to her.
A. It just reinforces my feeling that somebody was trying to influence my
thinking and thereby my testimony.
Egilman scoffed at Pfizer’s motion. He told BNET:
“They’re convicted felons [Pfizer took convictions as part of a Neurontin settlement with the Department of Justice and in the $2.3 Bextra settelement]. They’re convicted of fraud. People should consider that … when they read their accusations.”
Judge Patti Saris has yet to rule.
- Previously:
- Your Handy Neurontin Study Odds Calculator!
- Pfizer’s “Witness Tampering” Motion in Neurontin Case Is Denied
- Pfizer Email on “Negligible Evidence” for Neurontin as a Bipolar Drug Is Focus of Lawyers’ Tug-of-War
- Pfizer Accused of “Blatant Hypocrisy” Over Alleged Witness Tampering in Neurontin Case
- 2 Can Play That Game: Pfizer Claims Witness-Tampering in Neurontin Case
- Pfizer Defends Ex-CIA Agent Who “Terrified” Neurontin Witness
- Pfizer Investigator Stalked Neurontin Witness; Who Paid Off the Plaintiffs?
Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.
BNET User Analysis